Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.39
CYTX's Cash-to-Debt is ranked lower than
84% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CYTX: 0.39 )
Ranked among companies with meaningful Cash-to-Debt only.
CYTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.3  Med: 3.17 Max: N/A
Current: 0.39
Equity-to-Asset 0.25
CYTX's Equity-to-Asset is ranked lower than
83% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CYTX: 0.25 )
Ranked among companies with meaningful Equity-to-Asset only.
CYTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.83  Med: 0.14 Max: 0.94
Current: 0.25
-0.83
0.94
Piotroski F-Score: 2
Altman Z-Score: -19.44
Beneish M-Score: -3.07
WACC vs ROIC
17.56%
-132.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -215.85
CYTX's Operating Margin % is ranked lower than
58% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CYTX: -215.85 )
Ranked among companies with meaningful Operating Margin % only.
CYTX' s Operating Margin % Range Over the Past 10 Years
Min: -3958.33  Med: -244.92 Max: -131.11
Current: -215.85
-3958.33
-131.11
Net Margin % -240.81
CYTX's Net Margin % is ranked lower than
60% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CYTX: -240.81 )
Ranked among companies with meaningful Net Margin % only.
CYTX' s Net Margin % Range Over the Past 10 Years
Min: -3620.2  Med: -240.66 Max: -157.61
Current: -240.81
-3620.2
-157.61
ROE % -207.34
CYTX's ROE % is ranked lower than
89% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CYTX: -207.34 )
Ranked among companies with meaningful ROE % only.
CYTX' s ROE % Range Over the Past 10 Years
Min: -596.71  Med: -339.9 Max: -190.12
Current: -207.34
-596.71
-190.12
ROA % -68.58
CYTX's ROA % is ranked lower than
73% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CYTX: -68.58 )
Ranked among companies with meaningful ROA % only.
CYTX' s ROA % Range Over the Past 10 Years
Min: -127.5  Med: -64.74 Max: -49.06
Current: -68.58
-127.5
-49.06
ROC (Joel Greenblatt) % -1050.07
CYTX's ROC (Joel Greenblatt) % is ranked lower than
64% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CYTX: -1050.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CYTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1697.26  Med: -1143.13 Max: -620.81
Current: -1050.07
-1697.26
-620.81
3-Year Revenue Growth Rate -37.50
CYTX's 3-Year Revenue Growth Rate is ranked lower than
81% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CYTX: -37.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CYTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.25 Max: 88.4
Current: -37.5
0
88.4
3-Year EBITDA Growth Rate -39.10
CYTX's 3-Year EBITDA Growth Rate is ranked lower than
88% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CYTX: -39.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CYTX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -40.3  Med: -16.3 Max: 37.5
Current: -39.1
-40.3
37.5
3-Year EPS without NRI Growth Rate -39.70
CYTX's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CYTX: -39.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CYTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41.5  Med: -14 Max: 102.7
Current: -39.7
-41.5
102.7
GuruFocus has detected 3 Warning Signs with Cytori Therapeutics Inc $CYTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CYTX's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CYTX Guru Trades in Q2 2015

George Soros 22,400 sh (New)
» More
Q3 2015

CYTX Guru Trades in Q3 2015

George Soros Sold Out
» More
Q4 2016

CYTX Guru Trades in Q4 2016

Jim Simons 10,091 sh (New)
» More
Q1 2017

CYTX Guru Trades in Q1 2017

Jim Simons 40,091 sh (+297.29%)
» More
» Details

Insider Trades

Latest Guru Trades with CYTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 339112    SIC: 3841
Compare:NAS:NEOT, NAS:ADHD, NAS:DMPI, OTCPK:CVALF, NAS:OCRX, NAS:BVXV, NAS:CATB, OTCPK:MRNA, NAS:DMTX, AMEX:IBIO, AMEX:CANF, OTCPK:RGRX, NAS:VKTX, NAS:TPIV, AMEX:BPMX, NAS:DFFN, OTCPK:NWBO, OTCPK:GBLX, NAS:ONS, NAS:ICCC » details
Traded in other countries:XMPB.Germany,
Headquarter Location:USA
Cytori Therapeutics Inc develops cellular therapies designed to repair injured tissue, preserve function, improve quality of life, and modify disease progression.

Cytori Therapeutics Inc was incorporated in the State of Delaware in May 1997. The Company is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. Its core product is the Celution System, which extracts the naturally occurring ADRCs from a patient's own fat tissue and is CE Marked for a range of soft tissue procedures, including breast reconstruction. The company has completed three clinical trials using the Celution System for breast reconstruction, pipeline applications acute myocardial infarction, and chronic myocardial ischemia. It is involved in the European ADVANCE trial for acute myocardial infarction; and the U.S. trial for chronic myocardial ischemia. The company also sells StemSource cell banking line, including cell and tissue banking lines, as well as the Puregraft System that optimizes the fat graft preparation process. Its therapeutic areas comprises of cardiovascular disease, specifically refractory heart failure due to chronic myocardial ischemia, and the treatment of thermal burns. Its customers in Japan consist of researchers at academic hospitals and clinics. It also has a network of distributors who offer Celution Systems, instrumentation and consumables and Puregraft System to surgeons and hospitals throughout Europe. Celution Systems are or will be subject to stringent government regulation in the United States by the FDA under the Federal Food, Drug and Cosmetic Act.

Top Ranked Articles about Cytori Therapeutics Inc

Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial
Cytori Provides Latest Corporate Update at the 18th Annual B. Riley & Co. Institutional Investor Conference
One Year Follow Up of Cytori Cell Therapy™ in Investigator Erectile Dysfunction Trial
Cytori Therapeutics Announces Inducement Grants for New Employees
Cytori to Webcast First Quarter Financial Results on May 11
Cytori Announces Pricing of $9.5M Public Offering of Common Stock
Cytori Announces Proposed Public Offering of Common Stock
Cytori Receives U.S. FDA Approval for Burn Clinical Trial Related to BARDA Contract
Cytori Appoints Gregg Lapointe to Board of Directors
Cytori to Webcast Fourth Quarter Financial Results on March 23rd

SAN DIEGO, March 17, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its fourth quarter financial results and business update on Thursday, March 23, 2017 at 5:30 PM Eastern Time.
The dial-in information is as follows:
              Dial-In Number: 1.877.402.3914
              Conference ID: 90778155 Prior to the webcast at approximately 4:30 PM Eastern Time on March 23rd, Cytori will issue its fourth quarter earnings release which will review Cytori’s fourth quarter performance.  The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website. About Cytori Therapeutics, Inc. Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties. For more information, visit www.cytori.com.
Cytori Therapeutics, Inc.
Tiago Girao, 1.858.458.0900
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.33
CYTX's PB Ratio is ranked higher than
66% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CYTX: 3.33 )
Ranked among companies with meaningful PB Ratio only.
CYTX' s PB Ratio Range Over the Past 10 Years
Min: 2.12  Med: 28.83 Max: 797.32
Current: 3.33
2.12
797.32
PS Ratio 1.90
CYTX's PS Ratio is ranked higher than
86% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CYTX: 1.90 )
Ranked among companies with meaningful PS Ratio only.
CYTX' s PS Ratio Range Over the Past 10 Years
Min: 1.62  Med: 11.63 Max: 43.13
Current: 1.9
1.62
43.13
EV-to-EBIT -2.01
CYTX's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CYTX: -2.01 )
Ranked among companies with meaningful EV-to-EBIT only.
CYTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -16  Med: -4.8 Max: 63
Current: -2.01
-16
63
EV-to-EBITDA -2.10
CYTX's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CYTX: -2.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.5  Med: -5.1 Max: 31
Current: -2.1
-17.5
31
Current Ratio 0.94
CYTX's Current Ratio is ranked lower than
80% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CYTX: 0.94 )
Ranked among companies with meaningful Current Ratio only.
CYTX' s Current Ratio Range Over the Past 10 Years
Min: 0.94  Med: 2.85 Max: 26.46
Current: 0.94
0.94
26.46
Quick Ratio 0.62
CYTX's Quick Ratio is ranked lower than
81% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CYTX: 0.62 )
Ranked among companies with meaningful Quick Ratio only.
CYTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 2.57 Max: 24.95
Current: 0.62
0.62
24.95
Days Inventory 529.50
CYTX's Days Inventory is ranked lower than
96% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CYTX: 529.50 )
Ranked among companies with meaningful Days Inventory only.
CYTX' s Days Inventory Range Over the Past 10 Years
Min: 70.92  Med: 307.36 Max: 539.3
Current: 529.5
70.92
539.3
Days Sales Outstanding 31.64
CYTX's Days Sales Outstanding is ranked higher than
70% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CYTX: 31.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.15  Med: 64.69 Max: 124.26
Current: 31.64
4.15
124.26
Days Payable 169.76
CYTX's Days Payable is ranked higher than
81% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. CYTX: 169.76 )
Ranked among companies with meaningful Days Payable only.
CYTX' s Days Payable Range Over the Past 10 Years
Min: 25.87  Med: 116.71 Max: 414.3
Current: 169.76
25.87
414.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -63.20
CYTX's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CYTX: -63.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67  Med: -22.8 Max: 2.7
Current: -63.2
-67
2.7

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.17
CYTX's Price-to-Median-PS-Value is ranked higher than
93% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CYTX: 0.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CYTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 1.05 Max: 3.73
Current: 0.17
0.15
3.73
Earnings Yield (Greenblatt) % -50.25
CYTX's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CYTX: -50.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CYTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -53.05  Med: 2.2 Max: 2.8
Current: -50.25
-53.05
2.8

More Statistics

Revenue (TTM) (Mil) $10.07
EPS (TTM) $ -1.24
Beta2.86
Short Percentage of Float3.49%
52-Week Range $0.90 - 3.40
Shares Outstanding (Mil)32.48

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 11 25 71
EPS ($) -1.16 -0.47 1.40
EPS without NRI ($) -1.16 -0.47 1.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CYTX

Headlines

Articles On GuruFocus.com
Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial May 23 2017 
Cytori Provides Latest Corporate Update at the 18th Annual B. Riley & Co. Institutional Investor May 16 2017 
One Year Follow Up of Cytori Cell Therapy™ in Investigator Erectile Dysfunction Trial May 10 2017 
Cytori Therapeutics Announces Inducement Grants for New Employees May 05 2017 
Cytori to Webcast First Quarter Financial Results on May 11 Apr 27 2017 
Cytori Announces Pricing of $9.5M Public Offering of Common Stock Apr 11 2017 
Cytori Announces Proposed Public Offering of Common Stock Apr 10 2017 
Cytori Receives U.S. FDA Approval for Burn Clinical Trial Related to BARDA Contract Apr 10 2017 
Cytori Appoints Gregg Lapointe to Board of Directors Apr 03 2017 
Cytori to Webcast Fourth Quarter Financial Results on March 23rd Mar 17 2017 

More From Other Websites
ETFs with exposure to Cytori Therapeutics, Inc. : May 25, 2017 May 25 2017
Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 May 24 2017
Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial May 23 2017
Edited Transcript of CYTX earnings conference call or presentation 11-May-17 9:30pm GMT May 18 2017
Cytori Provides Latest Corporate Update at the 18th Annual B. Riley & Co. Institutional Investor... May 16 2017
Cytori reports 1Q loss May 11 2017
Cytori Reports First Quarter 2017 Business and Financial Results May 11 2017
One Year Follow Up of Cytori Cell Therapy™ in Investigator Erectile Dysfunction Trial May 10 2017
Cytori Therapeutics Announces Inducement Grants for New Employees May 05 2017
Cytori to Webcast First Quarter Financial Results on May 11 Apr 27 2017
Cytori Therapeutics Stock Sliding on Offering Price Discount Apr 11 2017
Cytori Therapeutics' stock plunges toward record low after stock offering prices at deep discount Apr 11 2017
Cytori Announces Pricing of $9.5M Public Offering of Common Stock Apr 11 2017
Today's Research Reports on Biotech Stocks to Watch: Cytori Therapeutics and Geron Apr 11 2017
Cytori Announces Proposed Public Offering of Common Stock Apr 10 2017
Cytori Get FDA Approval for Clinical Burn Trial Apr 10 2017
ETFs with exposure to Cytori Therapeutics, Inc. : April 10, 2017 Apr 10 2017
Cytori Rises on Crucial FDA Approval Apr 10 2017
Cytori Receives U.S. FDA Approval for Burn Clinical Trial Related to BARDA Contract Apr 10 2017
Cytori Appoints Gregg Lapointe to Board of Directors Apr 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)